CHAPTER 1 INTRODUCTION 2
STUDY GOALS AND OBJECTIVES 2
REASONS FOR DOING THE STUDY 2
SCOPE AND FORMAT 2
INTENDED AUDIENCE 3
METHODOLOGY 3
RELATED BCC RESEARCH REPORTS 3
ANALYST'S CREDENTIALS 3
BCC RESEARCH WEBSITE 4
DISCLAIMER 4
CHAPTER 2 SUMMARY 6
SUMMARY TABLE GLOBAL GASTRIC CANCER DIAGNOSTIC/SCREENING AND
TREATMENT MARKET, THROUGH 2020 ($ MILLIONS) 7
SUMMARY FIGURE GLOBAL GASTRIC CANCER DIAGNOSTIC/SCREENING AND
TREATMENT MARKET, 2014-2020 ($ MILLIONS) 7
CHAPTER 3 CANCER 9
WHAT IS CANCER? 9
CAUSES OF CANCER GROWTH 10
CANCER TREATMENT STRATEGIES 11
COMMON TREATMENTS AND PROBLEMS 11
Surgery 11
Chemotherapy 12
Radiation Treatment 12
Hormone Therapy 13
Targeted Therapy 13
GASTRIC CANCER 15
CHAPTER 4 INTRODUCTION TO GASTRIC CANCER 17
TABLE 1 MAIN CATEGORIES OF CANCER 17
DIGESTIVE SYSTEM AND CANCER 18
ESOPHAGEAL CANCER 18
GASTRIC CANCER GLOBAL INCIDENCE 21
SUBTYPES AND CHARACTERISTICS 22
SMALL INTESTINE CANCER 23
STOMACH CANCER/GASTRIC CANCER OVERVIEW 26
TABLE 2 TYPES OF STOMACH CANCER 29
TABLE 3 THE STAGES OF ADENOCARCINOMA STOMACH CANCER 29
TABLE 4 TESTS AND PROCEDURES USED TO DIAGNOSE STOMACH CANCER 30
CAUSES 32
TABLE 5 RISK FACTORS 32
TABLE 6 CAUSES OF GASTRIC CANCER 33
SYMPTOMS 33
TABLE 7 SYMPTOMS 33
THERAPEUTIC OPTIONS 34
RELATED CANCERS AND OVERVIEW 35
KIDNEY CANCER 35
TARGETED THERAPIES FOR KIDNEY CANCER 39
TABLE 8 DRUGS APPROVED FOR KIDNEY (RENAL CELL) CANCER 40
SORAFENIB (NEXAVAR) 40
SUNITINIB (SUTENT) 40
TEMSIROLIMUS (TORISEL) 41
EVEROLIMUS (AFINITOR) 41
BEVACIZUMAB (AVASTIN) 41
PAZOPANIB (VOTRIENT) 41
AXITINIB (INLYTA) 42
LIVER 42
PANCREATIC CANCER 46
SUMMARY 51
CHAPTER 5 GASTRIC CANCER SCREENING, DIAGNOSIS AND MARKET 53
SCREENING 53
SCREENING METHODS 53
TABLE 9 GASTRIC SCREENING METHODS 54
SCREENING AND BENEFITS 55
SCREENING MODALITIES 55
Barium-Meal Gastric Photofluorography 55
Gastric Endoscopy 56
Serum Pepsinogen 56
GASTRIC SCREENING IN UNITED STATES 57
GASTRIC CANCER SCREENING WORLDWIDE 57
Conclusions 58
CHAPTER 6 GASTRIC SCREENING AND DIAGNOSIS MARKET 60
TABLE 10 ESTIMATED INCIDENCE, MORTALITY AND PREVALENCE OF STOMACH
CANCER WORLDWIDE, 2012 (THOUSANDS) 60
SCREENING 61
TABLE 11 GLOBAL GASTRIC CANCER DIAGNOSTIC AND SCREENING MARKET,
THROUGH 2020 ($ MILLIONS) 62
DIAGNOSIS AND PROGNOSIS 64
TESTS 64
TABLE 12 TESTS AND PROCEDURES TO DETECT GASTRIC CANCER 64
IMAGING TESTS 65
Upper Gastrointestinal (GI) Series 66
Computed Tomography (CT or CAT) Scan 66
Magnetic Resonance Imaging (MRI) Scan 66
Positron Emission Tomography (PET) Scan 67
Chest X-Ray 67
Laparoscopy 67
Helicobacer Pylori 68
TABLE 13 TESTS USED TO DETECT H. PYLORI 68
Lab Tests 68
Costs 68
TABLE 14 GASTROINTESTINAL ENDOSCOPY EXAMINATIONS IN U.S., 2009
(MILLIONS) 68
SERUM PEPSINOGEN PREDICTS GASTRIC ADENOCARCINOMA 70
CHAPTER 7 GASTRIC CANCER TREATMENT OPTIONS 72
CURRENT PRACTICES 72
TABLE 15 TYPES OF STANDARD TREATMENT 72
CHEMOPREVENTION 72
ANTIOXIDANTS 72
ANTIBIOTICS 73
Non-Steroidal Anti-Inflammatory Drugs (Including Aspirin) 73
STAGING 73
Sentinel Lymph Node Mapping 73
Surgery 74
Chemotherapy 74
Radiation Therapy 75
Chemoradiation 75
TARGETED THERAPY 75
Drugs Approved for Stomach (Gastric) Cancer 75
TABLE 16 APPROVED DRUGS FOR GASTRIC CANCER 76
PROGNOSIS 76
PREVENTION 76
CHEMOTHERAPY DRUGS AND COMBINATIONS 77
TARGETED THERAPY OVERVIEW 77
Pembrolizumab 78
Ramucirumab 79
Afinitor (Everolimus) 81
Apatinib 85
FAILED DRUGS 86
Cetuximab 86
Tykerb (Lapatinib) 86
Expected Treatment Outcomes 87
GASTROINTESTINAL CANCER: MONOCLONAL ANTIBODIES 87
TABLE 17 RECENT SURFACE ANTIGENS TARGETED BY MARKETED ANTIBODY
THERAPEUTICS 88
TABLE 18 MONOCLONAL ANTIBODIES FOR GASTROINTESTINAL CANCER
TREATMENT 88
TABLE 19 GLOBAL SALES FOR BEST-SELLING MONOCLONAL ANTIBODIES FOR
GASTROINTESTINAL CANCER, 2014 ($ MILLIONS) 89
FIGURE 1 GLOBAL SALES FOR BEST-SELLING MONOCLONAL ANTIBODIES FOR
GASTROINTESTINAL CANCER, 2014 ($ MILLIONS) 89
TABLE 20 GASTRIC CANCER AND ANTIBODIES IN DEVELOPMENT 91
AVASTIN (BEVACIZUMAB) 91
HERCEPTIN (TRASTUZUMAB) 92
VECTIBIX (PANITUMUMAB) 94
CHAPTER 8 MARKET DYNAMICS AND OVERVIEW 96
TABLE 21 CANCER KEY FACTS 96
STANDARD TREATMENTS 97
GLOBAL CANCER MARKET TRENDS 97
TABLE 22 GLOBAL ESTIMATED INCIDENCE FOR CANCER BY REGION, 2009-2030
(MILLIONS OF PATIENTS) 98
FIGURE 2 GLOBAL ESTIMATED INCIDENCE FOR CANCER BY REGION, 2009-2030
(MILLION PATIENTS) 98
TABLE 23 GLOBAL CANCER RELATED ESTIMATED DEATHS BY REGION, 2012 AND
2030 (MILLIONS) 99
FIGURE 3 GLOBAL CANCER RELATED ESTIMATED DEATHS, BY REGION 2012 AND
2030 (MILLIONS) 99
TABLE 24 APPROVED ONCOLOGY DRUGS, 2013-2015 100
GLOBAL ONCOLOGY MARKET 101
TABLE 25 GLOBAL MARKET FOR ONCOLOGY DRUGS BY REGION, THROUGH 2020 ($
MILLIONS) 102
FIGURE 4 GLOBAL MARKET FOR ONCOLOGY DRUGS BY REGION, 2014-2020 ($
MILLIONS) 102
CANCER DRUGS: PAST PERFORMANCE 103
TABLE 26 GLOBAL SALES FOR ONCOLOGY DRUGS BY COMPANIES, 2012 AND 2013
($ MILLIONS/%) 105
EMERGING MARKETS 106
TABLE 27 ASIA-PACIFIC MARKET FOR ONCOLOGY DRUGS, THROUGH 2020 ($
MILLIONS) 106
FIGURE 5 ASIA-PACIFIC MARKET FOR ONCOLOGY DRUGS, 2014-2020 ($ MILLIONS) 106
GASTRIC CANCER TREATMENT COSTS 109
Drugs Approved for Stomach (Gastric) Cancer 110
TABLE 28 GLOBAL MARKET FOR GASTRIC CANCER, THROUGH 2020 ($ MILLIONS) 111
FIGURE 6 GLOBAL MARKET FOR GASTRIC CANCER, 2014-2020 ($ MILLIONS) 111
TABLE 29 APPROVED DRUGS FOR GASTRIC CANCER TREATMENT 111
TABLE 30 GLOBAL BIOTHERAPEUTICS SALES COMPARED TO TOTAL PRESCRIPTION
DRUG SALES, THROUGH 2020 ($ MILLIONS) 112
FIGURE 7 GLOBAL BIOTHERAPEUTICS SALES COMPARED TO TOTAL PRESCRIPTION
DRUG SALES, 2014-2020 ($ MILLIONS) 112
TABLE 31 GLOBAL SALES FOR APPROVED BIOLOGICAL TREATMENT OF GASTRIC
CANCER - MONOCLONAL ANTIBODIES, THROUGH 2020 ($ MILLIONS) 113
FIGURE 8 GLOBAL SALES FOR BIOLOGICAL TREATMENT OF CANCER -
MONOCLONAL ANTIBODIES, 2013-2020 ($ MILLIONS) 113
TABLE 32 GLOBAL SALES FOR POTENTIAL BIOLOGICAL TREATMENT OF GASTRIC
CANCER-MONOCLONAL ANTIBODIES, THROUGH 2020 ($ MILLIONS) 114
FIGURE 9 GLOBAL SALES FOR POTENTIAL BIOLOGICAL TREATMENT OF CANCER -
MONOCLONAL ANTIBODIES, 2013-2020 ($ MILLIONS) 114
DRUGS IN DEVELOPMENT 114
MAJOR PLAYERS 114
Roche 114
TABLE 33 PATENT EXPIRIES 115
Merck/Bristol-Myers Squibb 115
ISSUES AND TRENDS AFFECTING MARKET 116
SUMMARY 117
CHAPTER 9 GASTRIC CANCER TREATMENT AND PREVENTION MARKET SIZE AND
GROWTH 119
MARKET BY PRODUCT TYPE 121
CYRAMZA 121
Kadcyla (ado-trastuzumab emtansine) 122
Perjeta 122
Herceptin 123
ONCOLOGY MARKET AND GROWTH 123
Leading Drugs 123
TABLE 34 CANCER DRUGS SALES AND FORECAST, 2013-2016 ($ MILLIONS) 123
MARKET BY GEOGRAPHICAL SEGMENTS 124
TABLE 35 ONCOLOGY TREATMENT, 2013 (BILLIONS) 124
ONCOLOGY PIPELINE 125
U.S. Market 125
JAPAN (ASIA) MARKET 126
TABLE 36 JAPAN MARKET FOR BIOLOGICAL TREATMENT OF CANCER -
MONOCLONAL ANTIBODIES, THROUGH 2020 ($ MILLIONS) 126
FIGURE 10 JAPAN MARKET FOR BIOLOGICAL TREATMENT OF CANCERMONOCLONAL
ANTIBODIES, 2014-2020 ($ MILLIONS) 126
TABLE 37 JAPAN MARKET FOR BIOLOGICAL TREATMENT OF CANCER BY PRODUCT,
2008 AND 2009 ($ MILLIONS) 127
FIGURE 11 JAPAN MARKET FOR BIOLOGICAL TREATMENT OF CANCER BY PRODUCT,
2008 AND 2009 ($ MILLIONS) 127
EUROPE MARKET 128
TABLE 38 EUROPE MARKET FOR BIOLOGICAL TREATMENT OF CANCER -
MONOCLONAL ANTIBODIES, THROUGH 2020 ($ MILLIONS) 128
FIGURE 12 EUROPE MARKET FOR BIOLOGICAL TREATMENT OF CANCER -
MONOCLONAL ANTIBODIES, 2014-2020 ($ MILLIONS) 128
TABLE 39 EUROPE MARKET FOR BIOLOGICAL TREATMENT OF CANCER BY
PRODUCT, 2008 AND 2009 ($ MILLIONS) 128
ASIA MARKET 129
AUSTRALIA MARKET 129
SOUTH KOREA MARKET 129
CHINA MARKET 130
Gastric Cancer Market in China 130
TAIWAN MARKET 131
SINGAPORE MARKET 131
INDIA MARKET 132
BIOMAb-EGFR 133
TABLE 40 ASIA-PACIFIC COMPANIES IN ONCOLOGY 133
CHAPTER 10 PIPELINE, PATENTS AND NEW DEVELOPMENTS 135
RECENT DEVELOPMENTS AND APPROVALS 135
TABLE 41 APPROVED GASTRIC CANCER DRUGS, 2013-2014 136
NEW DRUGS/COMPANIES IN DEVELOPMENT 136
CLINICAL TRIALS IN ONCOLOGY 136
TABLE 42 ONCOLOGY CLINICAL TRIALS, 2009 136
FIGURE 13 ONCOLOGY CLINICAL TRIALS, 2009 136
Two New Clinical Trials for Advanced Gastric Cancer 137
TABLE 43 ROCHE - CLINICAL TRIALS 138
AZD4547 139
Pacific Edge 139
Oncolytics 140
CHAPTER 11 GLOBAL CANCER STATISTICS 142
CANCER TRENDS 142
TABLE 44 GLOBAL CANCER ESTIMATES, 2012 (MILLIONS) 142
TABLE 45 CANCER - NEW GLOBAL CASES DIAGNOSED, 2012 (EXCLUDING
NON-MELANOMA SKIN CANCER) 143
TABLE 46 COMMONLY DIAGNOSED CANCERS WORLDWIDE, 2012 (MILLIONS) 144
TABLE 47 AGE-STANDARDIZED RATE PER 100,000, 2012 145
TRENDS OVER TIME 146
FUTURE TRENDS 2020 147
TABLE 48 NUMBER OF NEW CANCER CASES BY SITE, 2020 (MILLIONS/%) 147
CANCER CURE AND COSTS 148
CAUSES OF RISE IN CANCER CASES 149
TABLE 49 AMERICAN CANCER SOCIETY RECOMMENDATIONS FOR CANCER
PREVENTION 149
PROJECTIONS TO 2030 150
TABLE 50 GLOBAL CANCER INCIDENCE AND DEATHS, 2012 AND 2030 (MILLIONS) 150
FIGURE 14 GLOBAL CANCER INCIDENCE AND DEATHS, 2012 AND 2030 (MILLIONS) 151
CURRENT CANCER TRENDS AND ECONOMIC BURDEN 152
The Burden of Cancer 152
EMERGING MARKETS 153
TABLE 51 GLOBAL INCIDENCE OF CANCER BY TYPE, 2012 (MILLIONS) 154
TABLE 52 GLOBAL MORTALITY OF CANCER BY TYPE, 2012 (MILLIONS) 154
CANCER PREVALENCE AND MARKET 155
GASTRIC CANCER 156
TABLE 53 ESTIMATED GASTRIC CANCERS BY REGION, 2012 (THOUSANDS) 157
TABLE 54 TOP 20 COUNTRIES WITH THE HIGHEST INCIDENCE OF GASTRIC CANCER 158
AFRICA 158
ASIA 162
Cancer Prevention and Screening in Asia 163
CHINA AND JAPAN 166
Gastric H. pylori infection 169
Japan 169
China 170
MALAYSIA 170
INDIA 170
EUROPE 172
THE AMERICAS 173
TABLE 55 AMERICAS: CANCER FACTS 173
NORTH AMERICA 175
TABLE 56 UNITED STATES: LEADING NEW CANCER CASES, 2014 175
TABLE 57 UNITED STATES - LEADING NEW CANCER CASES, 2014 176
Canada 176
New Cases of Cancer in 2013 177
TABLE 58 PERCENT DISTRIBUTION OF ESTIMATED NEW STOMACH CANCER CASES,
BY GENDER, IN CANADA, 2013 (%) 178
SUMMARY 178
CHAPTER 12 COMPANIES AND GLOBAL PLAYERS 180
COMPANIES 180
TABLE 59 GLOBAL PRESCRIPTION SALES FOR BIOLOGIC DRUGS, 2014 ($ MILLIONS) 180
CANCER MARKET DYNAMICS 180
SELECTED COMPANIES AND PROFILES 181
BIOGEN IDEC 181
BRISTOL MYERS SQUIBB 181
ELI LILLY AND COMPANY 181
GLAXOSMITHKLINE 182
GENENTECH, INC 183
Hoffmann-LA Roche INC. 183
IMMUNOGEN 183
MERCK & COMPANY 186
NOVARTIS 187
PFIZER 189
ROCHE/GENENTECH 189
ONCOLYTICS 190
PACIFIC EDGE DIAGNOSTICS NZ 191
ZOVA BIOTHERAPEUTICS INC. 191
CHAPTER 13 PARTNERS IN DEVELOPMENT 193
RESEARCH AND DEVELOPMENT PARTNERSHIP AGREEMENTS AND TECHNOLOGY
AND DIAGNOSTIC AGREEMENTS 193
CHAPTER 14 REFERENCES 195

LIST OF TABLES

SUMMARY TABLE GLOBAL GASTRIC CANCER DIAGNOSTIC/SCREENING AND
TREATMENT MARKET, THROUGH 2020 ($ MILLIONS) 7
TABLE 1 MAIN CATEGORIES OF CANCER 17
TABLE 2 TYPES OF STOMACH CANCER 29
TABLE 3 THE STAGES OF ADENOCARCINOMA STOMACH CANCER 29
TABLE 4 TESTS AND PROCEDURES USED TO DIAGNOSE STOMACH CANCER 30
TABLE 5 RISK FACTORS 32
TABLE 6 CAUSES OF GASTRIC CANCER 33
TABLE 7 SYMPTOMS 33
TABLE 8 DRUGS APPROVED FOR KIDNEY (RENAL CELL) CANCER 40
TABLE 9 GASTRIC SCREENING METHODS 54
TABLE 10 ESTIMATED INCIDENCE, MORTALITY AND PREVALENCE OF STOMACH
CANCER WORLDWIDE, 2012 (THOUSANDS) 60
TABLE 11 GLOBAL GASTRIC CANCER DIAGNOSTIC AND SCREENING MARKET,
THROUGH 2020 ($ MILLIONS) 62
TABLE 12 TESTS AND PROCEDURES TO DETECT GASTRIC CANCER 64
TABLE 13 TESTS USED TO DETECT H. PYLORI 68
TABLE 14 GASTROINTESTINAL ENDOSCOPY EXAMINATIONS IN U.S., 2009 (MILLIONS) 68
TABLE 15 TYPES OF STANDARD TREATMENT 72
TABLE 16 APPROVED DRUGS FOR GASTRIC CANCER 76
TABLE 17 RECENT SURFACE ANTIGENS TARGETED BY MARKETED ANTIBODY
THERAPEUTICS 88
TABLE 18 MONOCLONAL ANTIBODIES FOR GASTROINTESTINAL CANCER TREATMENT 88
TABLE 19 GLOBAL SALES FOR BEST-SELLING MONOCLONAL ANTIBODIES FOR
GASTROINTESTINAL CANCER, 2014 ($ MILLIONS) 89
TABLE 20 GASTRIC CANCER AND ANTIBODIES IN DEVELOPMENT 91
TABLE 21 CANCER KEY FACTS 96
TABLE 22 GLOBAL ESTIMATED INCIDENCE FOR CANCER BY REGION, 2009-2030
(MILLIONS OF PATIENTS) 98
TABLE 23 GLOBAL CANCER RELATED ESTIMATED DEATHS BY REGION, 2012 AND
2030 (MILLIONS) 99
TABLE 24 APPROVED ONCOLOGY DRUGS, 2013-2015 100
TABLE 25 GLOBAL MARKET FOR ONCOLOGY DRUGS BY REGION, THROUGH 2020 ($
MILLIONS) 102
TABLE 26 GLOBAL SALES FOR ONCOLOGY DRUGS BY COMPANIES, 2012 AND 2013
($ MILLIONS/%) 105
TABLE 27 ASIA-PACIFIC MARKET FOR ONCOLOGY DRUGS, THROUGH 2020 ($
MILLIONS) 106
TABLE 28 GLOBAL MARKET FOR GASTRIC CANCER, THROUGH 2020 ($ MILLIONS) 111
TABLE 29 APPROVED DRUGS FOR GASTRIC CANCER TREATMENT 111
TABLE 30 GLOBAL BIOTHERAPEUTICS SALES COMPARED TO TOTAL PRESCRIPTION
DRUG SALES, THROUGH 2020 ($ MILLIONS) 112
TABLE 31 GLOBAL SALES FOR APPROVED BIOLOGICAL TREATMENT OF GASTRIC
CANCER - MONOCLONAL ANTIBODIES, THROUGH 2020 ($ MILLIONS) 113
TABLE 32 GLOBAL SALES FOR POTENTIAL BIOLOGICAL TREATMENT OF GASTRIC
CANCER-MONOCLONAL ANTIBODIES, THROUGH 2020 ($ MILLIONS) 114
TABLE 33 PATENT EXPIRIES 115
TABLE 34 CANCER DRUGS SALES AND FORECAST, 2013-2016 ($ MILLIONS) 123
TABLE 35 ONCOLOGY TREATMENT, 2013 (BILLIONS) 124
HLC174A - Gastric Cancer Testing, Treatment and Prevention: Technologies and Global Markets
TABLE 36 JAPAN MARKET FOR BIOLOGICAL TREATMENT OF CANCER - MONOCLONAL
ANTIBODIES, THROUGH 2020 ($ MILLIONS) 126
TABLE 37 JAPAN MARKET FOR BIOLOGICAL TREATMENT OF CANCER BY PRODUCT,
2008 AND 2009 ($ MILLIONS) 127
TABLE 38 EUROPE MARKET FOR BIOLOGICAL TREATMENT OF CANCER -
MONOCLONAL ANTIBODIES, THROUGH 2020 ($ MILLIONS) 128
TABLE 39 EUROPE MARKET FOR BIOLOGICAL TREATMENT OF CANCER BY PRODUCT,
2008 AND 2009 ($ MILLIONS) 128
TABLE 40 ASIA-PACIFIC COMPANIES IN ONCOLOGY 133
TABLE 41 APPROVED GASTRIC CANCER DRUGS, 2013-2014 136
TABLE 42 ONCOLOGY CLINICAL TRIALS, 2009 136
TABLE 43 ROCHE - CLINICAL TRIALS 138
TABLE 44 GLOBAL CANCER ESTIMATES, 2012 (MILLIONS) 142
TABLE 45 CANCER - NEW GLOBAL CASES DIAGNOSED, 2012 (EXCLUDING
NON-MELANOMA SKIN CANCER) 143
TABLE 46 COMMONLY DIAGNOSED CANCERS WORLDWIDE, 2012 (MILLIONS) 144
TABLE 47 AGE-STANDARDIZED RATE PER 100,000, 2012 145
TABLE 48 NUMBER OF NEW CANCER CASES BY SITE, 2020 (MILLIONS/%) 147
TABLE 49 AMERICAN CANCER SOCIETY RECOMMENDATIONS FOR CANCER
PREVENTION 149
TABLE 50 GLOBAL CANCER INCIDENCE AND DEATHS, 2012 AND 2030 (MILLIONS) 150
TABLE 51 GLOBAL INCIDENCE OF CANCER BY TYPE, 2012 (MILLIONS) 154
TABLE 52 GLOBAL MORTALITY OF CANCER BY TYPE, 2012 (MILLIONS) 154
TABLE 53 ESTIMATED GASTRIC CANCERS BY REGION, 2012 (THOUSANDS) 157
TABLE 54 TOP 20 COUNTRIES WITH THE HIGHEST INCIDENCE OF GASTRIC CANCER 158
TABLE 55 AMERICAS: CANCER FACTS 173
TABLE 56 UNITED STATES: LEADING NEW CANCER CASES, 2014 175
TABLE 57 UNITED STATES - LEADING NEW CANCER CASES, 2014 176
TABLE 58 PERCENT DISTRIBUTION OF ESTIMATED NEW STOMACH CANCER CASES,
BY GENDER, IN CANADA, 2013 (%) 178
TABLE 59 GLOBAL PRESCRIPTION SALES FOR BIOLOGIC DRUGS, 2014 ($ MILLIONS) 180

LIST OF FIGURES

SUMMARY FIGURE GLOBAL GASTRIC CANCER DIAGNOSTIC/SCREENING AND
TREATMENT MARKET, 2014-2020 ($ MILLIONS) 7
FIGURE 1 GLOBAL SALES FOR BEST-SELLING MONOCLONAL ANTIBODIES FOR
GASTROINTESTINAL CANCER, 2014 ($ MILLIONS) 89
FIGURE 2 GLOBAL ESTIMATED INCIDENCE FOR CANCER BY REGION, 2009-2030
(MILLION PATIENTS) 98
FIGURE 3 GLOBAL CANCER RELATED ESTIMATED DEATHS, BY REGION 2012 AND
2030 (MILLIONS) 99
FIGURE 4 GLOBAL MARKET FOR ONCOLOGY DRUGS BY REGION, 2014-2020 ($
MILLIONS) 102
FIGURE 5 ASIA-PACIFIC MARKET FOR ONCOLOGY DRUGS, 2014-2020 ($ MILLIONS) 106
FIGURE 6 GLOBAL MARKET FOR GASTRIC CANCER, 2014-2020 ($ MILLIONS) 111
FIGURE 7 GLOBAL BIOTHERAPEUTICS SALES COMPARED TO TOTAL PRESCRIPTION
DRUG SALES, 2014-2020 ($ MILLIONS) 112
FIGURE 8 GLOBAL SALES FOR BIOLOGICAL TREATMENT OF CANCER - MONOCLONAL
ANTIBODIES, 2013-2020 ($ MILLIONS) 113
FIGURE 9 GLOBAL SALES FOR POTENTIAL BIOLOGICAL TREATMENT OF CANCER -
MONOCLONAL ANTIBODIES, 2013-2020 ($ MILLIONS) 114
FIGURE 10 JAPAN MARKET FOR BIOLOGICAL TREATMENT OF CANCER- MONOCLONAL
ANTIBODIES, 2014-2020 ($ MILLIONS) 126
FIGURE 11 JAPAN MARKET FOR BIOLOGICAL TREATMENT OF CANCER BY PRODUCT,
2008 AND 2009 ($ MILLIONS) 127
FIGURE 12 EUROPE MARKET FOR BIOLOGICAL TREATMENT OF CANCER -
MONOCLONAL ANTIBODIES, 2014-2020 ($ MILLIONS) 128
FIGURE 13 ONCOLOGY CLINICAL TRIALS, 2009 136
FIGURE 14 GLOBAL CANCER INCIDENCE AND DEATHS, 2012 AND 2030 (MILLIONS) 151